Search research articles
Contact Us
Filters
Showing results (21-30 of 91) with videos related to
Page
of 10
Sort By:
Cancer Management and Research
|
June 16, 2017
Can biosimilars help achieve the goals of US health care reform?
Ralph Boccia, Ira Jacobs, Robert Popovian, et al.
Lung Cancer (Amsterdam, Netherlands)
|
May 14, 2011
Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: meta-analysis of phase III trials
Geoffrey Y Ku, Benjamin A Haaland, Gilberto de Lima Lopes
Cancer Chemotherapy and Pharmacology
|
June 16, 2012
Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine matters
Geoffrey Y Ku, Benjamin A Haaland, Gilberto de Lima Lopes
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|
September 21, 2018
Global Health Perspective in Sarcomas and Other Rare Cancers
Vaia Florou, Antonio G Nascimento, Ashish Gulia, et al.
Expert Review of Clinical Pharmacology
|
October 24, 2013
Assessing the impact of substandard copy medicines in developing countries: the experience with imatinib copies
Anna Kaltenboeck, Genia Long, Eleanor Hayes-Larson, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|
June 1, 2017
The Road to Addressing Noncommunicable Diseases and Cancer in Global Health Policy
Heath Catoe, Jordan Jarvis, Sudeep Gupta, et al.
Journal of Global Oncology
|
July 19, 2017
Compulsory Licenses for Cancer Drugs: Does Circumventing Patent Rights Improve Access to Oncology Medications?
Cinthia Leite Frizzera Borges Bognar, Brittany L Bychkovsky, Gilberto de Lima Lopes
Current Opinion in Oncology
|
March 20, 2013
Pharmacoeconomic issues in head and neck oncology
Jonas A de Souza, Gilberto de Lima Lopes, Ezra E W Cohen
Pharmacoeconomics - Open
|
January 20, 2021
A Review of Cost-Effectiveness Studies of Pembrolizumab Regimens for the Treatment of Advanced Non-small Cell Lung Cancer
Nan Qiao, Ralph Insinga, Gilberto de Lima Lopes Junior, et al.
Cancer Letters
|
December 31, 2013
A novel anti-cancer agent, acetyltanshinone IIA, inhibits oestrogen receptor positive breast cancer cell growth by down-regulating the oestrogen receptor
Ting Yu, Zhicai Zhou, Yuguang Mu, et al.
Page
of 10
Search research articles
Search
Showing results (21-30 of 91) with videos related to
Sort By:
Page
of 10
Cancer Management and Research
|
June 16, 2017
Can biosimilars help achieve the goals of US health care reform?
Ralph Boccia, Ira Jacobs, Robert Popovian, et al.
Lung Cancer (Amsterdam, Netherlands)
|
May 14, 2011
Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: meta-analysis of phase III trials
Geoffrey Y Ku, Benjamin A Haaland, Gilberto de Lima Lopes
Cancer Chemotherapy and Pharmacology
|
June 16, 2012
Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine matters
Geoffrey Y Ku, Benjamin A Haaland, Gilberto de Lima Lopes
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|
September 21, 2018
Global Health Perspective in Sarcomas and Other Rare Cancers
Vaia Florou, Antonio G Nascimento, Ashish Gulia, et al.
Expert Review of Clinical Pharmacology
|
October 24, 2013
Assessing the impact of substandard copy medicines in developing countries: the experience with imatinib copies
Anna Kaltenboeck, Genia Long, Eleanor Hayes-Larson, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|
June 1, 2017
The Road to Addressing Noncommunicable Diseases and Cancer in Global Health Policy
Heath Catoe, Jordan Jarvis, Sudeep Gupta, et al.
Journal of Global Oncology
|
July 19, 2017
Compulsory Licenses for Cancer Drugs: Does Circumventing Patent Rights Improve Access to Oncology Medications?
Cinthia Leite Frizzera Borges Bognar, Brittany L Bychkovsky, Gilberto de Lima Lopes
Current Opinion in Oncology
|
March 20, 2013
Pharmacoeconomic issues in head and neck oncology
Jonas A de Souza, Gilberto de Lima Lopes, Ezra E W Cohen
Pharmacoeconomics - Open
|
January 20, 2021
A Review of Cost-Effectiveness Studies of Pembrolizumab Regimens for the Treatment of Advanced Non-small Cell Lung Cancer
Nan Qiao, Ralph Insinga, Gilberto de Lima Lopes Junior, et al.
Cancer Letters
|
December 31, 2013
A novel anti-cancer agent, acetyltanshinone IIA, inhibits oestrogen receptor positive breast cancer cell growth by down-regulating the oestrogen receptor
Ting Yu, Zhicai Zhou, Yuguang Mu, et al.
Page
of 10